Victor Freixinos-Rodriguez

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Dynamic Contrast-enhanced CT to Evaluate Early Response in Neuroendocrine Liver Metastases Treated With Everolimus and Radiation.

Dynamic Contrast-enhanced CT to Evaluate Early Response in Neuroendocrine Liver Metastases Treated With Everolimus and Radiation.

Journal: Anticancer research

Published: April 26, 2022

Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials.

Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 21, 2022

Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study.

Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study.

Journal: Cancers

Published: December 21, 2021

Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With?

Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With?

Journal: Current oncology reports

Published: March 31, 2021

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors.

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors.

Journal: Scientific reports

Published: October 01, 2020

Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era.

Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 01, 2020

A pilot study of everolimus and radiation for neuroendocrine liver metastases.

A pilot study of everolimus and radiation for neuroendocrine liver metastases.

Journal: Endocrine-related cancer

Published: May 10, 2020

Corrigendum to 'Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients' [Gynecologic Oncology 152 (2019) 270-277].

Corrigendum to 'Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients' [Gynecologic Oncology 152 (2019) 270-277].

Journal: Gynecologic oncology

Published: November 21, 2019

Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer.

Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer.

Journal: Gynecologic oncology

Published: January 07, 2019

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.

Journal: Gynecologic oncology

Published: September 12, 2018

Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.

Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.

Journal: Gynecologic oncology

Published: September 11, 2018

Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer.

Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer.

Journal: ESMO open

Published: September 10, 2018

Showing 1-12 of 20

Last Updated: 09/26/2026